Asthma and Allergy News and Research

FDA Grants Breakthrough Therapy Designation for Tezepelumab for Severe Asthma

AstraZeneca and its partner Amgen Inc. (Amgen) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma, without an eosinophilic phenotype, who are receiving inhaled corticosteroids/long-acting beta2-agonists with or without oral corticosteroids and additional asthma controllers.

Aetna Decides FeNO Testing Is Medically Necessary for Its Members With Asthma

Circassia Pharmaceuticals, Inc., a specialty pharmaceutical company focused on respiratory disease, is pleased to announce that Aetna, one of the largest health insurance companies in the United States, has updated its Exhaled Breath Tests Clinical Policy to include the measurement of exhaled nitric oxide as “medically necessary” for the evaluation of asthma and for monitoring the response to long-term control therapy.

Walgreens Locations Will Now Carry AUVI-Q Epinephrine Auto-Injectors

Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q® 0.15 mg and 0.3 mg available through Walgreens locations nationwide. This comes in an effort to help thousands of Americans with their epinephrine needs during the back to school season, as supply issues have been reported to the U.S. Food and Drug Administration (FDA) by other manufacturers.

Asthma Medication Recall Alert: Montelukast Tablets From Camber Pharmaceuticals for Incorrect Drug in Bottle

The U.S. Food and Drug Administration is warning consumers and health care professionals about a voluntary recall of one lot of Montelukast Sodium Tablets – lot number MON17384, expiration 12/31/2019 – by Camber Pharmaceuticals, Inc., Piscataway, N.J. Sealed bottles labeled as montelukast sodium tablets, 10 milligram, 30-count bottle from Camber were found to instead contain 90 tablets of Losartan Potassium Tablets, 50 mg.

FDA Approves First Generic Competitor of EpiPen Epinephrine Auto-Injector

The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds. Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.

Study Shows Anti-Viral Medicine Reduces Flu Symptoms in People With High-Risk Conditions, Like Asthma

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study’s primary objective, and showed superior efficacy in the primary endpoint of time to improvement of influenza symptoms versus placebo.

New Pediatric Asthma Yardstick Provides Health Care Professionals a Roadmap for Managing Asthma in Children

Although about 10 percent of school-aged children in the United States have asthma, there are few comprehensive U.S. guidelines for treating pediatric asthma. The Pediatric Asthma Yardstick, a new guideline from the American College of Allergy, Asthma and Immunology (ACAAI), offers a user-friendly “operational document”. It helps health care professionals understand which controller treatments are right for which age groups and identifies when a step up is needed.

Study Shows Mepolizumab to Be a Safe and Effective Long-Term Treatment Option for Severe Asthma

The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control New study showed one third of patients had no exacerbations on long-term treatment with Nucala GlaxoSmithKline plc (GSK) today presented new data from the longest study of an anti-IL5 biologic treatment in severe...

Managing the Stress of Asthma in Boston, Massachusetts, the #11 Asthma Capital

As Nancy Gomez knows, managing a child’s severe asthma can take a big toll on a parent’s time, finances and emotions. Nancy’s 10-year-old son, Oziel, has had asthma and allergies since he was a baby. Today Oziel has environmental allergies to pollen, animals, dust, smoke and more. His allergies, exercise and cold weather all trigger his asthma. On top of this, Oziel also has life-threatening food allergies. And he is autistic. Managing all of this is a constant challenge.

×
×
×
×